FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
haura nar raananaa	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Deuel (Last)	Name and Address of Reporting Person* Deuel Thomas Last) (First) (Middle) C/O ENZON PHARMACEUTICALS, INC.							Issuer Name and Ticker or Trading Symbol ENZON PHARMACEUTICALS INC [ENZN] Date of Earliest Transaction (Month/Day/Year) 04/19/2010									ng Pe	10% O Other (below)	wner	
685 ROUTE 202/206 (Street) BRIDGEWATER NJ 08807						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc	Form	al or Joint/Group Filing (Check Applicable orm filed by One Reporting Person orm filed by More than One Reporting erson				
(City)	(St	ate) (Zip)																	
		Tab	le I - N	on-Deriv	ative S	Sec	urit	ies Ac	quired, D)isp	osed o	of, or B	enefi	ciall	y Owne	d				
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day						Execution Date,			Transaction Disposi Code (Instr. and 5)			rities Acc ed Of (D)			5. Amo Securit Benefic Owned Follow	ies cially	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code V		Amoun	t (A)	or F	Price	Report Transa			u. 4)	(11151111111111111111111111111111111111					
Common Stock ⁽¹⁾ 04/19/2					2010			A		7,137	7,137 ⁽²⁾ A		\$0	7,137			D			
		Ta	able II						uired, Dis , options						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Dee Execution if any (Month/	med	4. Transac Code (II		5. N of Deri Sec Acq (A) Disp of (I	umber ivative urities uired or posed D) tr. 3, 4	6. Date Exer Expiration ((Month/Day	ble and				B. Price of Derivative Security Instr. 5)	Beneficial	O Fo D (I) (1)	10. Ownership Form: Direct (D) or Indirect I) (Instr.	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amo or Num of Shar	ber						
Stock Option (right to buy) ⁽³⁾	\$10.51	04/19/2010			A			17,673	(4)	04.	/19/2020	Common Stock	17,6	573	\$0	17,673		D		

Explanation of Responses:

- 1. Restricted stock units granted by Enzon Pharmaceuticals, Inc. ("Enzon") pursuant to Enzon's 2001 Stock Incentive Plan and qualified under Rule 16b-3(d).
- 2. Of the 7,137 shares granted, 2,379 will vest on April 19, 2011, 2,379 will vest on April 19, 2012, and the remaining 2,379 will vest on April 19, 2013 so long as Dr. Deuel is a member of Enzon's board of directors on the above dates.
- $3.\ Stock\ options\ granted\ by\ Enzon\ pursuant\ to\ Enzon's\ 2001\ Incentive\ Stock\ Plan\ and\ qualified\ under\ Rule\ 16b-3(d).$
- 4. Of the 17,673 options granted by Enzon, 5,891 will vest on April 19, 2011, 5,891 will vest on April 19, 2012, and the remaining 5,891 will vest on April 19, 2013 so long as Dr. Deuel is a member of Enzon's board of directors on the above dates.

<u>/s/ Thomas F. Deuel</u> <u>04/27/2010</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.